Moral standards for research in developing countries: From "reasonable availability" to "fair benefits"

Hastings Center Report

Volumn 34, Issue 3, 2004, Pages 17-27

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ANALYTICAL APPROACH; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES; DEVELOPING COUNTRY; ETHICS; HEALTH CARE AND PUBLIC HEALTH; HEALTH CARE DELIVERY; HUMAN; INTERNATIONAL COOPERATION; MORALITY; RESEARCH ETHICS; REVIEW; SOCIAL BEHAVIOR; THAILAND;

ANALYTICAL APPROACH; BIOMEDICAL AND BEHAVIORAL RESEARCH; COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES; HEALTH CARE AND PUBLIC HEALTH;

CLINICAL TRIALS; DEVELOPING COUNTRIES; ETHICS, RESEARCH; HEALTH SERVICES ACCESSIBILITY; HEPATITIS A VACCINES; HUMANS; INTERNATIONAL COOPERATION; MORALS; SOCIAL RESPONSIBILITY; THAILAND;

EID: 4644265447     PISSN: 00930334     EISSN: None     Source Type: Journal    
DOI: 10.2307/3528416     Document Type: Conference Paper

References (53)

1. M. Barry, "Ethical Considerations of Human Investigation in Developing Countries: the AIDS Dilemma," NEJM 319 (1988) 1083-86;
2. M. Angell, "Ethical Imperialism? Ethics in International Collaborative Clinical Research," NEJM 319 (1988): 1081-83;
3. N.A. Christakas, "The Ethical Design of an AIDS Vaccine Trial in Africa," Hastings Center Report 18, no. 3 (1988): 31- 37.
4. P. Lurie and S.M. Wolfe, "Unethical Trials of Interventions to Reduce Perinatal Transmission of the Human Immunodeficiency Virus in Developing Countries," NEJM 337 (1997): 853-56;
5. M. Angell, "The Ethics of Clinical Research in the Third World," NEJM 337 (1997): 847-49;
6. H. Varmus and D. Satcher, "Ethical Complexities of Conducting Research in Developing Countries," NEJM 337 (1997): 1003-1005;
7. R. Crouch and J. Arras, "AZT Trials and Tribulations," Hastings Center Report 28, no. 6 (1998): 26-34;
8. C. Grady, "Science in the Service of Healing," Hastings Center Report 28, no. 6 (1998): 34-38;
9. R.J. Levine, "The 'Best Proven Therapeutic Method' Standard in Clinical Trials in Technologically Developing Countries," IRB 20 (1998): 5-9;
10. B.R. Bloom, "The Highest Attainable Standard: Ethical Issues in AIDS Vaccines," Science 279 (1998): 186-88.
11. World Medical Association. Declaration of Helsinki, 2000 at www.wma.net/e/policyl 2-c-e.html; Council for International Organizations of Medical Science, International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva: CIOMS, 1993);
12. P. Wilmshurst, "Scientific Imperialism: If They Won't Benefit from the Findings, Poor People in the Developing World Shouldn't be Used in Research," BMf 314 (1997): 840-41;
13. P.E. Cleaton-Jones, "An Ethical Dilemma: Availability of Anti-retroviral Therapy after Clinical Trials with HIV Infected Patients are Ended," BMJ 314 (1997): 887-88.
14. CIOMS, International Ethical Guidelines, 1993.
15. World Medical Association Declaration of Helsinki.
16. Medical Research Council of the United Kingdom, Interim Guidelines-Research Involving Human Participants in Developing Societies: Ethical Guidelines for MRC-spon- sored Studies (London: MRC, 1999);
17. Joint United National Programme on HIV/AIDS (UNAIDS), Ethical Considerations in HPV Preventive Vaccine Research (Geneva: UN- AIDS, 2000);
18. National Consensus Conference, Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda (Kampala, Uganda: National Consensus Conference, 1997);
19. Medical Research Council of South Africa, Guidelines on Ethics for Medical Research (South Africa: Medical Research Council, 1993).
20. L.H. Glantz et al., "Research in Developing Countries: Taking 'Benefit" Seriously," Hastings Center Report28, no. 6 (1998): 38-42;
21. G.J. Annas and M.A. Grodin, "Human Rights and Maternal-Fetal HIV Transmission Prevention Trials in Africa," American Journal of Public Health 88 (1998): 560-63.
22. H.T. Shapiro and E.M. Meslin, "Ethical Issues in the Design and Conduct of Clinical Trials in Developing Countries," NEJM 345 (2001): 139-42.
23. See also National Bioethics Advisory Commission, Ethical and Policy Issues in International Research: Clinical Trials in Developing Countries (Washington D.C.: U.S. Government Printing Office, 2001).
24. Annas and Grodin, "Human Rights and Maternal-Fetal HIV Transmission Prevention Trials in Africa."
25. E.J. Emanuel, D. Wendler, and C. Grady, "What Makes Clinical Research Ethical?" JAMA 283 (2000): 2701-711;
26. E.J. Emanuel et al., "What Makes Clinical Research in Developing Countries Ethicial? The Benchmarks of Ethical Research," Journal of Infectious Diseases 189 (2004): 930- 37.
27. Ibid.; R.J. Levine, Ethical and Regulatory Aspects of Clinical Research, 2nd Edition (New Haven, Conn.: Yale University Press, 1988).
28. N. Black, "Evidence based policy: proceed with care," BMJ 323 (2001): 275- 9.
29. Wilmshurst, "Scientific Imperialism," and National Consensus Conference, Guidelines for the Conduct of Health Research Involving Human Subjects in Uganda; L.H. Glantz et al., "Research in Developing Countries: Taking 'Benefit" Seriously;" G.J. Annas and M.A. Grodin, "Human Rights and Maternal-Fetal HIV Transmission Prevention Trials in Africa."
30. Glantz et al., "Research in Developing Countries."
31. CIOMS, International Ethical Guidelines for Biomedical Research Involving Human Subjects, 2nd edition (Geneva: CIOMS, 2002).
32. A. Wertheimer, Exploitation (Princeton, N.J.: Princeton University Press, 1999), chapter 1; N.A. Christakis, "The Ethical Design of an AIDS Vaccine Trial in Africa," Hastings Center Report 28 (1998): 31-37.
33. Wertheimer, Exploitation.
34. A. W Wood, "Exploitation," Social Philosophy and Policy 12 (1995): 135-58.
35. Wertheimer, Exploitation.
36. Buchanan, Ethics, Efficiency and the Market, p.87.
37. C. Korsgaard, "The Reasons We Can Share: An Attack on the Distinction Between Agent-relative and Agent-neutral Values," in Creating the Kingdom of Ends (New York: Cambridge University Press, 1996).
38. Wertheimer, Exploitation.
39. J. Rawls, A Theory of Justice, 2nd edition (Cambridge, Mass.: Harvard University Press, DATE).
40. Wertheimer, Exploitation.
41. CIOMS, International Ethical Guidelines for Biomedical Research Involving Human Subjects.
42. CIOMS, International Ethical Guidelines for Biomedical Research Involving Human Subjects, 2nd edition.
43. I. Chalmers, "What is the Prior Probability of a Proposed New Treatment being Superior to Established Treatments?" BMJ 314 (1997): 74-75;
44. B. Djulbegovic et al., "The Uncertainty Principle and Industry-Sponsored Research," Lancet 356 (2000): 635-38.
45. NBAC, Ethical and Policy Issues in International Research.
46. Participants in the 2001 Conference on Ethical Aspects of Research in Developing Countries,"Fair Benefits from Research in Developing Countries," Science 298 (2002): 2133-34.
47. Emanuel, Wendler, and Grady, "What Makes Clinical Research Ethical?" and Levine, Ethical and Regulatory Aspects of Clinical Research; J. Rawls, The Law of Peoples (Cambridge, Mass.: Harvard University Press, 1999).
48. T. Pogge, World Poverty and Human Rights (Cambridge, U.K.: Polity Press, 2002), chapters 1 and 4.
49. B.I. Innis et al. "Protection against Hepatitis A by an Inactivated Vaccine," JAMA TJX (1994): 1328-34.
50. C. Hoke et al., "Protection against Japanese Encephalitis by Inactivated Vaccines," NEJM 319 (1988): 608-614.
51. C.A. Kozik et al., "Causes of Death and Unintentional Injury among School Children in Thailand," Southeast Asian Journal of Tropical Medicine and Public Health 30 (1999): 129-35.
52. "Interview with Prof Natth," Good Clinical Practice Journal 6, no. 6 (1999): 11.
53. A. Gutmann and D. Thompson, Democracy and Disagreement (Cambridge, Mass.: Harvard University Press, 1996).